TRENTON, N.J. (AP) — U.S. regulators have approved a second gene therapy for blood cancer. The one-time treatment is for aggressive lymphoma in adults. The Food and Drug Administration approved sales of the therapy from Kite Pharma on Wednesday. The treatment involves removing immune system cells called T cells from a patient, reprogramming them to target and kill cancer cells and giving them back to the patient.